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Conclusion: AHRT is a reasonable alternative to conventional 
fractionated radiotherapy in stage I-II NSCLC without access 
to SABR and in stage III patients unfit for concurrent 
chemotheraphy. In both groups, treatment was well tolerated 
without grade 3 or higher treatment-related toxicity. PS >2 
was an independent risk factor for OS and CSS. 
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Purpose or Objective: Since 2014, the VERO system 
equipped with dynamic tracking DT has been used in our 
center for lung SBRT.The purpose of this work is to compare 
2 compensation techniques for lung SBRT, DT and a method 
based on the definition of an ITV, in terms of PTV volume 
reduction and treatment time. 
 
Material and Methods: The VERO is an O ring system 
equipped with a gimbaled linac allowing pan and tilt 
rotations and with a stereoscopic dual-source kV X-ray 
imaging allowing the guidance of the tracking. A 4DCT is done 
to measure the range of the target movements with the 
breath: if the amplitude is < 7mm, an ITV is determined on 
the MIP images and if it is > 7mm, the DT method is 
preferred. A gold marker (Visicoil, IBA) is then implanted in 
the lesion and a new 4DCT is realized 1 week later. The 
GTVDT is drawn on the exhale phase and the PTVDT is 
defined with a 5mm margin. The dose is prescribed on the 
isodose covering 95 % of the PTV (Monte Carlo): the 
peripheral tumors receive 3x17 Gy, near the thoracic wall 
4x12 Gy and near the mediastin 8x7,5 Gy. The metastatic 
diseases received 5x10 Gy. For DT, treatments are delivered 
with 6-8 no coplanar beams. 
 
Results: 77 patients were treated with lung SBRT, including 
22 patients treated with DT. Among these 22 patients, the 
PTVITV was however estimated: the average size of the 
PTVDT was 28.8cc(6.5 - 14.3 cc) and that of the PTVITV was 
46.4cc(10.4 in 139 cc), so a 40 % reduction of the PTV 
volume. The average session length in DT was 35 min, the 
same as with the ITV method. The breathing rate of the 
patients was often irregular during the session and especially 
compared with the reference 4DCT. It did not affect the 
treatment delivery neither the guidance of the tracking. The 
clinical tolerance during and after the SBRT with tracking was 
excellent: 1 patient that was already treated for interstitial 
pulmonary fibrosis developed symptomatic radiation 
pneumonitis (RP). 5 other patients had radiological RP on the 
CT done during their first 6 months follow up period ; all of 
them received corticosteroid therapy and did not show any 
symptoms. There was no chest wall toxicity. Over a 16 
months follow-up,1 patient did not benefit from treatment 
with DT SBRT and had a progressive disease. 
 
Conclusion: With a 40% reduction of the PTV, this DT 
technique makes it easy to monitor all the patients breathing 
motion, including very irregular rates, in a treatment time 
equivalent to more classical techniques based on the ITV. 
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Purpose or Objective: Local failure in lung cancer is 
associated with extremely poor survival. This study tested 
whether the pattern of failure is associated with the most 
PET avid volume in the pre-therapeutic PET/CT scan. 
 
Material and Methods: Patients with inoperable NSCLC 
treated in our department between 2008 and 2010 were 
reviewed. Forty patients, who received radiotherapy (RT) for 
NSCLC and had an accessible pre-therapeutic FDG PET/CT 
scanning, were included. Fifteen of the patients developed 
local failure as the first event. Patient and tumour 
characteristics for patients with recurrences are presented in 
Table 1. The peak SUV area in the pre-therapeutic PET/CT 
scan in both tumor and lymph nodes were identified by an 
experienced nuclear physician who delineated the volume 
encompassing 50% of the maximum SUV (SUVmax50) in all 
fifteen patients. All patients were followed by CT scans every 
third month. The CT scans which showed recurrences (rCT) 
were imported to the Eclipse treatment planning system 
(Varian MS) and the recurrence gross tumor volume(s) (rGTV) 
was delineated. A rigid registration between pre-therapeutic 
PET/CT and treatment planning CT (pCT) was performed 
using a soft tissue match on the tumor or the lymph nodes in 
SmartAdapt (Varian MS). The SUVmax50 volumes were copied 
to pCT using the rigid registration. The rCT with the defined 
rGTV were also fused with the pCT using a rigid registration 
based on normal tissue nearby the rGTV but excluding the 
rGTV. The vertebral column or the aortic arch was found to 
be preferable. Two radiation oncologists assessed the rigid 
registration between pCT and rCT. 
 
Results: The patients received conventionally fractionated 
RT with a total dose of 60-66 Gy. Planning target volumes 
(PTV) ranged from 169 cm3 to 1065 cm3 (mean = 678 cm3). 
Median time to local progression was seven months (95% CI 5-
9 months). In twelve patients, the recurrences of the primary 
tumor appeared inside the PTV. In three cases, the 
recurrences were both inside and outside the PTV. These 
three recurrences outside the PTV appeared in mediastinal 
lymph node region. The rGTV overlapped with the pre-
therapeutic PET sub-volumes in twelve patients (Figure 1). In 
one case, rGTV was near the PET sub-volume area without 
overlapping. In one patient, part of the target was missed 
because an atelectasis obscured the PET/CT signal and made 
the delineation of GTV less optimal. 
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Conclusion: This retrospective study shows that the 
SUVmax50 pre-therapeutic signal correlates with the post-
therapeutic recurrences in the majority of patients. Pre-
therapeutic PET/CT or planning PET/CT is a useful tool to 
guide the future dose escalation studies. 
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Purpose or Objective: 
Background: There is great potential to utilise a large range 
of retrospective clinical data as an evidence base in decision 
support systems (DSS) for cancer prognosis and subsequent 
personalised treatment decisions. Recently, there were 
several DSSs built for this purpose using machine learning 
tools, mainly regression models, Bayesian Networks (BN) and 
Support Vector Machines (SVM). These machine learning tools 
provide only a prediction of a class (decision), based on input 
attributes that were used to build the model, without 
providing additional information to clinicians about how and 
why this prediction was made. 
Objective: To investigate the performance of an alternative 
machine learning tool in building a lung cancer radiotherapy 
DSS that provides clinicians with an estimated prediction 
together with the influencing attributes and their values 
(evidence) in supporting the decision reached. This will 
provide contextual justification to clinicians regarding the 
decisions, which will further help them in deciding whether 
to adopt the machine prediction or not. 
 
Material and Methods: A Non-Small Cell Lung Cancer 2 year 
survival prediction model was built, using data at Liverpool 
Cancer Therapy Centre in NSW, Australia. The attributes used 
to predict the survival were age, gender, ECOG, GTV and 
FEV1. The machine learning tool used is a Decision Tree 
which automatically extracts rules from the training data and 
formulates these as if-then-else patterns. A report of the 
used rules during the prediction process indicates the 
effective attributes used to reach the decision. SVM, 
Regression models and BN were built and tested using the 
same data set; however, BN possess less, and SVM/Regression 
models possess none, of this reporting capability as they are 
learned by analysing probabilities and numerical distances 
among data points associated with prediction class. 
 
Results: The DSS was learnt within the Liverpool Clinic with 
an unfiltered cohort of 4650 4686 patients. After filtering out 
patient records with missing values for the used attributes 
the cohort was reduced to 97 patients treated radically. The 
area under curve of the Decision Tree, SVM, Regression Model 
and BN when tested using a rigorous 10 fold cross-validation 
method respectively was 0.62, 0.62, 0.63 and 0.6. There is no 
significant difference in the performance between the four 
tools examined, however, the decision tree also generates an 
understandable context with every prediction made as a list 
of supporting attributes like the example in Figure 1. 
 
 
 
Conclusion: It is possible to build a DSS for NSCLC data that 
provides a prediction with additional information justifying 
the decision with similar performance as the commonly 
utilised SVM, BN and regression tools. To improve the 
performance and avoid over fitting, more diverse and 
complete training data is needed by incorporating data from 
other centres to the learning process using distributed 
learning. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
is an attractive modality for the definitive treatment of 
oligometastatic or unresectable primary lung malignancies. 
Proximity of the tumor to adjacent organs-at-risk (OAR) may 
limit delivery of a sufficiently ablative dose. The ability to 
adapt to tumor response during treatment may improve OAR 
sparing and/or allow dose escalation. This study aimed to 
evaluate the degree of daily interfractional variation in gross 
tumor volume (GTV) during SBRT for patients with 
oligometastatic or unresectable primary malignancy of the 
central thorax using a magnetic resonance image guided 
radiotherapy (MR-IGRT) treatment system. 
 
Material and Methods: Eleven patients with unresectable 
primary or oligometastatic malignancy of the central thorax 
were treated at our institution with extended fractionation 
SBRT on a clinical MR-IGRT system. Treatment regimens 
consisted of 60 Gy in 12 fractions (n=8) or 62.5 Gy in 10 
fractions (n=3). For each treatment fraction, low-field (0.35 
Tesla) MR setup imaging was acquired as part of routine 
clinical practice. Daily GTV was retrospectively defined on 
MR image sets for all patients at each of 10 or 12 fractions, 
using initial GTVs from CT simulation as a template. Daily 
tumor volumes were then recorded and compared for each 
patient to evaluate for interfractional change in tumor 
volume. 
